Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apta-3
- Development stage
- Preclinical
- Lead developer
- Aptahem
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Apta-3 is a preclinical-stage synthetic RNA aptamer therapeutic being developed by the Swedish biotechnology company Aptahem. It is part of a portfolio of multifunctional aptamers designed to address life-threatening conditions by modulating coagulation, inflammation, and immune system responses. Developed using the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) method, Apta-3 is intended to bind to specific target molecules with high affinity and specificity. As of current reports, Apta-3 has not yet been activated for active development, manufactured, or studied, and its specific molecular target and primary therapeutic indication remain undisclosed by the developer.
Beyond the preview
Go deeper on Apta-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apta-3.